Kornimate/medical-research-clean huggingface dataset:
screening and prevalence of adolescent idiopathic scoliosis in selected urban and countryside schools in egypt

Conditions: Scoliosis

Summary: early detection of scoliosis and determination of which areas are more affected urban or countryside will help in early management. also, this will guide the government and the community for early intervention to decrease the factors that leads to this postural abnormality. this also will guide another clinician to search for the cause of these posture deformities and to concentrate screening for special areas with special cultures.

scoliosis may have an impact on the egyptian society as children between 10-15 years old represent 9.5 % of the population which is the third large category appendix (3). so without the early detection of adolescent idiopathic scoliosis for that age group, bad impacts will be implemented for egyptian society by causing disabilities and psychological problems for these children. the early detection of scoliosis is of a great importance as curve detection before skeletal maturation gives a good opportunity for early treatment or prevention of curve progression. scoliosis has a bad effect on cosmetic appearance, quality of life, psychological well-being, disability, back pain, breathing function. it may also progress in adulthood and need further treatment. so a multidimensional and comprehensive evaluation of scoliosis patients is necessary to design a complete therapeutic approach.

Eligibility criteria:
inclusion criteria: 1. age range from 10 to 15 years. 2. males students. 3. students who have structural scoliosis. exclusion criteria: 1. congenital deformities. 2. recent fracture and there is a fixation in the upper or the lower extremities 3. neuromuscular disorder (cerebral palsy and spinal muscle atrophy). 4. syndromic disorders (muscular dystrophy, osteogenesis imperfect, and spina-bifida).

Keywords: scoliosis, prevalence screening, egypt
priority-matching correction technique in degenerative lumbar scoliosis

Conditions: Degenerative Lumbar Disease; Scoliosis; Degenerative Scoliosis

Summary: surgical outcomes, including radiographic outcomes, patient-reported outcomes, postoperative complications, and revision surgery rates, were compared in patients with degenerative lumbar scoliosis (dls) who underwent correction surgery with reference to our priority-matching correction technique and the standard reported by obeid and colleagues. our findings may provide tangible guidance for surgical decision-making in dls.


Eligibility criteria:
inclusion criteria: 1. a diagnosis of dls based on radiography and previous medical record, 2. age \&gt; 50 years exclusion criteria: 1. leg length discrepancy, 2. a history of spinal or pelvic surgery, 3. a history of neuromuscular diseases, arthritis or tumor.
t-icd vs s-icd shocks: myocardial injuries

Conditions: ICD Shock Myocardial Injuries

Summary: implantable cardioverter defibrillator (icd) shocks are associated with a subsequent increased risk of death, and an elevation of cardiac enzymes has been measured after defibrillation testing (dft). the aim of our study was to investigate the association between s-icd vs t-icd shocks and acute cardiac damage in humans, as evaluated by means of sensitive and highly specific circulating biomarkers


Eligibility criteria:
inclusion criteria: patients who met the criteria for icd implantation according to the current guidelines exclusion criteria: -
dietary protein and hepatic fat accumulation

Conditions: Hepatic Fat Accumulation; Nonalcoholic Fatty Liver Disease

Summary: the objective of this study is to investigate the potential beneficial effect of increasing protein in the diet in order to decrease hepatic lipid accumulation on a high-fat diet. the investigators hypothesize that increasing protein in a high-fat diet suppresses lipid accumulation in the liver, and that changes in (hepatic) fat handling underlie this reduced lipid accumulation.


Eligibility criteria:
inclusion criteria: * healthy * body mass index (bmi) 18-25 kg/ m2; * stable dietary habits; * physical activity levels. * caucasian exclusion criteria: * unable or unwilling to comply with study procedures; * not caucasian * unstable body weight (weight gain or loss \> 3 kg in the past three months); * moderate intense physical activity (exercise) for more than 4 hours/week; * (chronic) disease which might influence the study outcomes e.g. diabetes mellitus or any other endocrine disorder, active cardiovascular disease, hepatic disease, renal disease, cancer; * family history of diabetes mellitus; * use of medication, except incidental use of paracetamol; * abuse of drugs; * alcohol consumption of more than 14 glasses per week; * participation in another biomedical study within 1 months prior to the first screening visit; * contraindications to mri scanning. these contraindications include patients with one of the following conditions: * claustrophobia; * central nervous system aneurysm clips; * implanted neural stimulator; * implanted cardiac pacemaker or defibrillator; * cochlear implant; * ocular foreign body (e.g. metal shavings); * insulin pump; * metal shrapnel or bullet; * or metal containing corpora aliena in the eye of brains.

Keywords: hepatic fat accumulation dietary protein nafld
pharmacological recruitment of endogenous neural precursors to promote pediatric white matter repair: establishing correlations between visual outcomes, saccadic function and meg oscillations in children with demyelinating disorders in comparison to healthy control children

Conditions: Demyelinating Disease

Summary: the neural circuits in our brains require a layer of insulation in order to transmit signals in a rapid and efficient fashion. this insulation is called white matter and is comprised of a specific type of brain cell called an oligodendrocytes. damage to brain white matter occurs following injury and in disorders like multiple sclerosis and results in sensory, motor, and cognitive problems. currently there are no effective medical therapies to promote brain repair and reduce disability following damage to white matter. in this project, we hope to change the situation by encouraging the brain itself to generate new oligodendrocytes and thus new white matter. our first step is to find measures sensitive to white matter growth.


Eligibility criteria:
inclusion criteria: * experienced a demyelinating event (only applicable to patient subjects) * between the ages of 5 years to 18 years and 11 months of age * has either english as his or her native language or has had at least two years of schooling in english exclusion criteria: * children with non-demyelinating etiologies of white matter dysfunction (i.e., metabolic disorders, vasculitis, and non-specific mri abnormalities * is younger than 5 years of age * is 18 years and 11 of age or older * has a prior history of traumatic brain injury, neurological disorder, cerebral palsy, developmental delay, or learning disability * requires sedation for brain scanning * is claustrophobic, as brain scanning requires children to enter a tunnel in the mri machine
protocol for the clinical evaluation of lyophilized amniotic fluid in the treatment of knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: to evaluate the efficacy of lyophilized amniotic fluid as compared to the saline injection, placebo control in the treatment of moderate osteoarthritis of the knee.

approximately 180 subjects will be enrolled in one of three dose arms ( 4ml, saline placebo and 4ml 2x). the estimated enrollment period is 6 months. each subject will receive 1 injection and be evaluated for efficacy and safety during a 6 month observation period. the study is expected to be completed within 12 months, inclusive of enrollment and follow-up for all subjects.

Eligibility criteria:
inclusion criteria: 1. subject is 30 years or older. 2. subject has a diagnosis of osteoarthritis (oa) defined as grade 1 to 3 on the kellgren lawrence grading scale. 3. subject is willing and able provide informed consent and participate in all procedures and follow-up evaluations necessary to complete the study. 4. subject must have a vas pain scale greater than 30. exclusion criteria: 1. subject has active infection at the injection site. 2. subject has rheumatoid arthritis, psoriatic arthritis, or have been diagnosed with any other auto-immune disorders that could be the cause of their knee pain. 3. bmi greater than 45 kg/m2 4. subject has received an intra-articular hyaluronic acid (ha) injection for the treatment of oa of the target knee within 12 weeks prior to screening. 5. subject has received a steroid or platelet rich plasma (prp) injection for the treatment of oa of the target knee within 12 weeks prior to screening. 6. subject has had major surgery or arthroscopy in the target knee within 26 weeks of treatment or plans to have surgery in the target knee within 180 days of treatment. 7. subject is pregnant or plans to become pregnant within 180 days of treatment. 8. subject has used an investigational drug, device or biologic within 12 weeks prior to treatment. 9. subject has any significant medical condition that, in the opinion of the investigator, would interfere with protocol evaluation and participation. 10. subject has a history of immunosuppressive or chemotherapy in the last 5 years 11. subject has autoimmune disease or a known history of having acquired immunodeficiency syndromes (aids) or hiv 12. subject has had prior radiation at the site 13. subject is currently taking anticoagulant therapy (excluding plavix or aspirin) 14. new diagnosis of gout in the past 6 month 15. subject has a diagnosis of osteoarthritis (oa) defined as grade 4 on the kellgren lawrence grading scale. 16. subject has a diagnosis of osteonecrosis of the knee. 17. subject has had a total knee replacement.
clinical study to investigate the long-term safety, tolerability, and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this study is an extension to the study ac-058b201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.


Eligibility criteria:
inclusion criteria: 1. patients who completed study treatment at their regular week 24 (end of treatment) visit within the core study ac-058b201. 2. signed informed consent for participating in the extension study. exclusion criteria: 1. any clinically relevant medical or surgical condition, which, in the opinion of the investigator, would put the patient at risk by participating in the extension study.
epo-4-rhesus study

Conditions: Erythroblastosis, Fetal; Erythroblastosis Fetalis, Rh Disease; Erythroblastosis Fetalis Due to RH Antibodies; Erythroblastosis Fetalis Due to Isoimmunization

Summary: up to 80% of infants with hemolytic disease due to maternal alloimmunization, treated with iut, require at least one top-up transfusion for late anemia during the first 3 months of life. erythropoietin deficiency is also considered as a possible contributing factor to late anemia and therefore we will assess the role of epo (darbepoetin alfa) in the treatment of these infants.

the mainstay of antenatal treatment of fetal anemia due to red cell alloimmunization is (serial) iut. the mainstay of postnatal treatment in hdn is (1) intensive phototherapy and exchange transfusion to treat hyperbilirubinemia and prevent kernicterus, and (2) top-up transfusions to treat anemia. up to 80% of infants with hdn treated with iut require at least one top-up transfusion for late anemia during the first 3 months of life. several risk factors for late anemia have been reported, including serial iut (due to bone marrow suppression), severity of hdn, reduced use of exchange transfusions during the neonatal period and reduced survival of transfused red blood cells. finally, erythropoietin deficiency is also considered as a possible contributing factor to late anemia. epo has been increasingly used in neonates to prevent or reduce neonatal anemia without short or long-term adverse effects. several small studies and casuistic reports suggest that neonates with hdn may benefit from treatment with epo to reduce the risk of delayed anemia and subsequent top-up transfusions. however, other authors found that epo may be less effective than expected. due to the lack of evidence, routine use of epo is currently not recommended. to determine a role for epo in this group of patients, a well-designed randomized controlled clinical trial of sufficient sample size is required. potentially, epo stabilizes the hemoglobin levels of these infants and thus prevents top-up transfusions and extra admissions, creating a more stable and natural postnatal course for patients with hdn.

Eligibility criteria:
inclusion criteria: * all (near)-term neonates (gestational age ≥ 35 weeks) admitted to the leiden university medical center (lumc) with hdfn, treated with iut. exclusion criteria: * none.

Keywords: hemolytic disease of the fetus and newborn hdfn red blood cell alloimmunization
bmi and lymph node count in colorectal cancer

Conditions: The Aim of This Study is to Determine the Influence of BMI and Lymph Node Status on OS in CRC Patients in the Long Term

Summary: background and aim: colorectal cancer (crc) is one of the most frequent cancer entities in the western world. it is known that obesity is one of the major risk factors for crc. in contrast, mild obesity seems to have a positive effect on postoperative outcome, which is known as the "obesity paradox". also, the number of resected lymph nodes (ln) during surgery is very important for correct staging. the aim of the present project is to evaluate the impact of bmi and ln-yield on long term overall survival (os) of crc patients treated with curative intent. methods: patients treated for crc between 1998 and 2011 at the klinik favoriten in vienna, austria were analyzed in this retrospective single-center cohort analysis concerning os.


Eligibility criteria:
inclusion criteria: * colorectal carcinoma * treated at the klinik favoriten between 1998 and 2011 * elective or acute surgical setting * curative intent * older than 18 years exclusion criteria: * other carcinoma (anal, metastases, ...) * treated before 1998 or after 2011 * palliative intent * younger than 18 years

Keywords: colorectal cancer, survival, prognostic factors, body mass index, obesity paradox, lymph node count
china s3 pms: sapien 3 china post market registry study

Conditions: Aortic Stenosis, Severe

Summary: the objective of this study is to evaluate the long term safety and effectiveness of the sapien 3 transcatheter heart valve system in real world setting.

this is an observational, single-arm, multicentre, post-market study.

Eligibility criteria:
inclusion criteria: 1. patient with symptomatic, severe, calcified aortic stenosis who is appropriate for the treatment with transcatheter aortic valve replacement as determined by a heart team and will undergo tavi with the edwards sapien 3 system as part of standard-of-care treatment 2. all surgical risks as determined by the site heart team 3. the subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent. exclusion criteria: 1. medical, social, or psychological conditions that preclude appropriate consent and follow-up, including subjects under guardianship 2. considered to be part of a vulnerable population 3. pre-existing mechanical or bioprosthetic aortic valve 4. active sars-cov-2 infection or previously diagnosed with covid-19 with sequelae that could confound endpoint assessments 5. cannot tolerate an anticoagulation/antiplatelet regimen 6. evidence of intracardiac mass, thrombus, vegetation, active infection or endocarditis 7. tortuous or calcified vessels that would prevent safe entry of the dilators and sheath 8. participating in a drug or device study that has not reached its primary endpoint

Keywords: transcatheter aortic valve implantation (tavi) transcatheter aortic valve replacement (tavr) sapien 3 heart disease cardiovascular disease
clinical study of dexmedetomidine administered intranasally to relieve perioperative anxiety and depression in patients with colorectal tumors

Conditions: Colorectal Cancer

Summary: currently, domestic and international research on dexmedetomidine as well as anxiety and depression is more focused on basic research. in terms of clinical research, dexmedetomidine is more often used in pediatrics, short surgeries, intensive care units, etc., for sedation and analgesia; while less research has been done for the relief of anxiety and depression. at present, on the one hand, the number of oncology patients is on the rise both at home and abroad, and on the other hand, anxiety and depression account for an increasing proportion of healthcare in the world. tumor patients, as a high prevalence group of anxiety and depression, their prognosis and regression are also more complicated. therefore, exploring the role of intranasal administration of dexmedetomidine in relieving perioperative anxiety and depression in oncology patients has a very strong practical basis and clinical significance.


Eligibility criteria:
inclusion criteria: 1. patients with a preoperative diagnosis of colorectal cancer who were to undergo their first oncologic procedure 2. patients who opted for general anesthesia via orotracheal intubation 3. age ≥18 years old 4. asa classification ii-iii (5) 18.0 \< bmi \< 30.0 5. signed informed consent. exclusion criteria: 1. diagnosed mental illness or cognitive impairment, or taking antipsychotic, sedative-hypnotic, or anxiolytic-depressant medications 2. serious abnormalities of liver or kidney function. 3. prior alcohol or drug abuse 4. second or third degree atrioventricular block, severe sinus bradycardia (\<50 beats/min), sick sinus node syndrome, congenital heart disease, and other cardiac arrhythmias that severely affect hemodynamic stability 5. grade 3 hypertension 6. any disease of the head, such as cerebral infarcts, epilepsy, head trauma, etc. 7. confirmed diagnosis of non-tumor-induced chronic ( ≥3 months) neuropathic pain 8. inability to understand the meaning of the scale and complete the scoring. 9. women preparing for pregnancy, pregnant women, or breastfeeding 10. patients with myasthenia gravis 11. respiratory function score ≥3
autonomic profiles in pediatric patients with cyclic vomiting syndrome (cvs), irritable bowel syndrome (ibs),postural orthostatic tachycardia syndrome (pots), functional abdominal pain (fap) or chronic nausea

Conditions: Vomiting Syndrome; Irritable Bowel Syndrome; Postural Orthostatic Tachycardia Syndrome; Abdominal Pain; Chronic Nausea

Summary: retrospectively review the charts of all children who had heart rate variability, deep breathing test, valsalva maneuver, tilt table test, thermoregulatory sweat testing, quantitative sudomotor axon reflex test (qsart) completed and were cared for at children's hospital of wisconsin.


Eligibility criteria:
inclusion criteria: * outpatient services exclusion criteria: * inpatient services

Keywords: chart must reveal the following procedures: heart rate variability, deep breathing test, valsalva maneuver, table test, thermoregulatory sweat testing, quantitative sudomotor axon reflex test (qsart), vital signs, postural changes in heart rate and blood pressure, composite autonomic score
evaluating acceptance of new liquid somatropin formulation in children with growth hormone deficiency

Conditions: Growth Hormone Disorder; Growth Hormone Deficiency in Children; Genetic Disorder; Turner Syndrome

Summary: this trial is conducted in asia. the aim of this trial is to evaluate the new liquid somatropin formulation in children with growth hormone deficiency.


Eligibility criteria:
inclusion criteria: * written informed consent by patient and/or guardian/parents * patients with one of the following diagnosis: growth failure due to growth hormone deficiency (ghd), turner syndrome, or growth retardation in children with chronic renal disorders * patients who are willing to inject themselves and answer questionnaires or young patients whose parents/guardian are willing to inject their child and answer questionnaires * patients on growth hormone therapy for at least 6 weeks before entering the trial exclusion criteria: * pregnancy or breast feeding women * suspected or known allergy to trial product * other daily injection therapy (non-growth hormone, e.g insulin-therapy) * participating in any other trial involving other investigational products within the last 3 months
comparison of the clinical efficacy of 2 paravertebral block strategies in thoracic surgery by thoracotomy: by the anesthetist (paravertebral block guided by ultrasound) and by the thoracic surgeon (paravertebral block visual)

Conditions: Pain

Summary: post-thoracotomy pain is one of the most severe. the local analgesia allows its effective control and a reduction of postoperative morbidity and mortality. the gold standard for local analgesia is the thoracic epidural. however, this technique can be dangerous with severe complications. the paravertebral block showed comparable efficacy to the thoracic epidural for local analgesia . in addition, it has a better safety profile. there are several installation techniques. the difference in efficiency of these laying techniques is unknown.

compare the clinical effectiveness of two strategies of realization of paravertebral block: by the anesthetist before incision (paravertebral block guided by ultrasound) and by the thoracic surgeon at chest closure (paravertebral block visual).

Eligibility criteria:
inclusion criteria: * patient with thoracotomy indication for segmentectomy (s), lobectomy (s) lung or pulmonary wedge resection * patient consenting to participate to the study * patient enrolled in the national healthcare insurance program * patient older than 18 years exclusion criteria: * patient with neuropathy * patient with body mass index superior to 35 kg/m2 * patient with contraindication for paravertebral block or local analgesia

Keywords: thoracic surgery thoracotomy